Microbial and Biochemical Pharmacy

current position:

Home - Education - Master Supervisor - Microbial and Biochemical Pharmacy

LV Kai

Source:

time:2021-12-09

Views:


NameKai Lv

Department: Department of Organic Chemistry

Tel: (8610)63165280

Email: lvkai@imb.pumc.edu.cn

Research Experience

2017/08 - Now Associate Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2016/04 - 2017/07 Assistant Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2015/11 - 2016/04 Lecturer, School of Pharmacy, Hebei Medical University

2012/10 - 2015/10 Postdoctoral Researcher, Department of Chemistry, Purdue University

Education

2009/09 - 2012/07 Ph.D. in microbial and biochemical pharmacy, Peking Union Medical College

2006/09 - 2009/07 Master in Medicinal Chemistry, Hebei Medical University & Academy of Military Medical Sciences

2002/09 – 2006/07 Bachelor in Pharmacy, Hebei Medical University

Research Field

Drug discovery; Antivirus research; Antitubercular research; Antibacterial research

Research Interests

Our group is a medicinal chemistry group focused on the discovery of anti-infections drug candidates. Specifically, we are interested in the anti-virus, anti-TB, and anti-bacterial research area.

Traditional SAR-based methods, structure and/or ligand-based computational approaches are employed to optimize the scaffold of the lead compounds. All the target compounds are synthesized and evaluated for their activity in vitro. Selected compounds are appraised for their PK, toxicity, and in vivo activity, et al. Our compound, TZY-5-84 with potent anti-TB activity in vitro and in vivo, have been found to show good drug-properties.

Selected Publications

[1] K. Lv, S. Wu, W. Li, Y. Geng, M. Wu, J. Zhou, Y. Li, Q. Gao, M. Liu, Design, synthesis and anti-HBV activity of NVR3-778 derivatives, Bioorganic chemistry, 94 (2020) 103363.

[2] K. Lv, W. Li, S. Wu, Y. Geng, A. Wang, L. Yang, M. Huang, K. Chowdhury, Y. Li, M. Liu, Amino acid prodrugs of NVR3-778: Design, synthesis and anti-HBV activity, Bioorganic & medicinal chemistry letters, 30 (2020) 127103.

[3] H. Wang, K. Lv (Co-first author),, X. Li, B. Wang, A. Wang, Z. Tao, Y. Geng, B. Wang, M. Huang, M. Liu, H. Guo, Y. Lu, Design, synthesis and antimycobacterial activity of novel nitrobenzamide derivatives, Chinese Chemical Letters, 30 (2019) 413-416.

[4] A. Wang, K. Lv (Co-first author),, Z. Tao, J. Gu, L. Fu, M. Liu, B. Wan, S.G. Franzblau, C. Ma, X. Ma, B. Han, A. Wang, S. Xu, Y. Lu, Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents, European journal of medicinal chemistry, 181 (2019) 111595.

[5] A. Wang, K. Lv (Co-first author),, L. Li, H. Liu, Z. Tao, B. Wang, M. Liu, C. Ma, X. Ma, B. Han, A. Wang, Y. Lu, Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents, European journal of medicinal chemistry, 178 (2019) 715-725.

[6] K. Lv, A. Wang, Z. Tao, L. Fu, H. Liu, B. Wang, C. Ma, H. Wang, X. Ma, B. Han, A. Wang, K. Zhang, M. Liu, Y. Lu, hERG optimizations of IMB1603, discovery of alternative benzothiazinones as new antitubercular agents, European journal of medicinal chemistry, 179 (2019) 208-217.

[7] Z. Tao, R. Cao, Y. Yan, G. Huang, K. Lv*, W. Li, Y. Geng, L. Zhao, A. Wang, Q. He, J. Yang, S. Fan, M. Huang, H. Guo, W. Zhong, M. Liu, Design, synthesis and in vitro anti-Zika virus evaluation of novel Sinefungin derivatives, European journal of medicinal chemistry, 157 (2018) 994-1004.

[8] K. Lv, Z. Tao, Q. Liu, L. Yang, B. Wang, S. Wu, A. Wang, M. Huang, M. Liu, Y. Lu, Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety, European journal of medicinal chemistry, 151 (2018) 1-8.

[9] L. Li, K. Lv (Co-first author), Y. Yang, J. Sun, Z. Tao, A. Wang, B. Wang, H. Wang, Y. Geng, M. Liu, H. Guo, Y. Lu, Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents, ACS medicinal chemistry letters, 9 (2018) 741-745.

[10] R. Zhang, K. Lv (Co-first author), B. Wang, L. Li, B. Wang, M. Liu, H. Guo, A. Wang, Y. Lu, Design, synthesis and antitubercular evaluation of benzothiazinones containing an oximido or amino nitrogen heterocycle moiety, Rsc Adv, 7 (2017) 1480-1483.

[11] L. Tang, Z. Bei, Y. Song, L. Xu, H. Wang, D. Zhang, Y. Dou, K. Lv*, H. Wang, Synthesis and in vivo antimalarial activity of novel naphthoquine derivatives with linear/cyclic structured pendants, Future medicinal chemistry, 9 (2017) 1117-1127.

[12] K. Lv, X. You, B. Wang, Z. Wei, Y. Chai, B. Wang, A. Wang, G. Huang, M. Liu, Y. Lu, Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents, ACS medicinal chemistry letters, 8 (2017) 636-641.

[13] K. Lv, L. Li, B. Wang, M. Liu, B. Wang, W. Shen, H. Guo, Y. Lu, Design, synthesis and antimycobacterial activity of novel imidazo[1,2-a]pyridine-3-carboxamide derivatives, European journal of medicinal chemistry, 137 (2017) 117-125.